These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31209257)

  • 21. Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
    Dillard P; Köksal H; Maggadottir SM; Winge-Main A; Pollmann S; Menard M; Myhre MR; Mælandsmo GM; Flørenes VA; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
    Mol Ther; 2021 Mar; 29(3):1199-1213. PubMed ID: 33212301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
    Morgan RA; Chinnasamy N; Abate-Daga D; Gros A; Robbins PF; Zheng Z; Dudley ME; Feldman SA; Yang JC; Sherry RM; Phan GQ; Hughes MS; Kammula US; Miller AD; Hessman CJ; Stewart AA; Restifo NP; Quezado MM; Alimchandani M; Rosenberg AZ; Nath A; Wang T; Bielekova B; Wuest SC; Akula N; McMahon FJ; Wilde S; Mosetter B; Schendel DJ; Laurencot CM; Rosenberg SA
    J Immunother; 2013 Feb; 36(2):133-51. PubMed ID: 23377668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.
    Goff SL; Johnson LA; Black MA; Xu H; Zheng Z; Cohen CJ; Morgan RA; Rosenberg SA; Feldman SA
    Cancer Immunol Immunother; 2010 Oct; 59(10):1551-60. PubMed ID: 20628878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visualization of the human CD4⁺ T-cell response in humanized HLA-DR4-expressing NOD/Shi-scid/γc(null) (NOG) mice by retrogenic expression of the human TCR gene.
    Takahashi T; Katano I; Ito R; Ito M
    Biochem Biophys Res Commun; 2015 Jan; 456(1):219-24. PubMed ID: 25462565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.
    Miyahara Y; Naota H; Wang L; Hiasa A; Goto M; Watanabe M; Kitano S; Okumura S; Takemitsu T; Yuta A; Majima Y; Lemonnier FA; Boon T; Shiku H
    Clin Cancer Res; 2005 Aug; 11(15):5581-9. PubMed ID: 16061876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1.
    Marcinkowski B; Stevanović S; Helman SR; Norberg SM; Serna C; Jin B; Gkitsas N; Kadakia T; Warner A; Davis JL; Rooper L; Hinrichs CS
    J Immunother Cancer; 2019 Aug; 7(1):229. PubMed ID: 31455429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
    Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
    Okada S; Muraoka D; Yasui K; Tawara I; Kawamura A; Okamoto S; Mineno J; Seo N; Shiku H; Eguchi S; Ikeda H
    Cancer Sci; 2023 Nov; 114(11):4172-4183. PubMed ID: 37675556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
    Hughes MS; Yu YY; Dudley ME; Zheng Z; Robbins PF; Li Y; Wunderlich J; Hawley RG; Moayeri M; Rosenberg SA; Morgan RA
    Hum Gene Ther; 2005 Apr; 16(4):457-72. PubMed ID: 15871677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
    Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI
    J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
    Clay TM; Custer MC; Spiess PJ; Nishimura MI
    Pathol Oncol Res; 1999; 5(1):3-15. PubMed ID: 10079371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.
    Giannoni F; Hardee CL; Wherley J; Gschweng E; Senadheera S; Kaufman ML; Chan R; Bahner I; Gersuk V; Wang X; Gjertson D; Baltimore D; Witte ON; Economou JS; Ribas A; Kohn DB
    Mol Ther; 2013 May; 21(5):1044-54. PubMed ID: 23380815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
    Sun L; Guo H; Jiang R; Lu L; Liu T; He X
    Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.
    Fontana R; Bregni M; Cipponi A; Raccosta L; Rainelli C; Maggioni D; Lunghi F; Ciceri F; Mukenge S; Doglioni C; Colau D; Coulie PG; Bordignon C; Traversari C; Russo V
    Blood; 2009 Feb; 113(8):1651-60. PubMed ID: 19074732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
    Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
    J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
    Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
    Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4.
    Coles CH; McMurran C; Lloyd A; Hock M; Hibbert L; Raman MCC; Hayes C; Lupardus P; Cole DK; Harper S
    J Biol Chem; 2020 Aug; 295(33):11486-11494. PubMed ID: 32532817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.